Indaptus Therapeutics Says Antitumor Platform Demonstrates Preclinical Efficacy Across Cancer Indications

Indaptus Therapeutics Inc INDP announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the company's Decoy anti-tumor platform.
Decoy10 demonstrated a 90% reduction of LPS-endotoxin activity and the use of 100% killed, non-pathogenic bacteria.
Decoy10 inhibited tumor growth and metastasis and induced tumor regressions as a single agent.
Regressions were also seen with Decoy10 in combination with a non-steroidal anti-inflammatory drug (NSAID), an anti-PD-1 checkpoint inhibitor, low-dose chemotherapy (LDC), and LDC plus a targeted antibody.
Regressions were durable and associated with immunological memory-mediated rejection of tumor rechallenge.
In vivo anti-tumor activity was seen with colorectal, breast, hepatocellular, pancreatic carcinomas, and non-Hodgkin's lymphomas (mouse and human) in preclinical models.
In December 2022, the company initiated its Phase 1 dose escalation and expansion clinical trial of Decoy20 in patients with advanced solid tumors where currently approved therapies have failed.
The Phase 1 study has begun with a single dose escalation followed by an expansion with continuous administration of Decoy20.
Price Action: INDP shares are up 5.08% at $2.59 on the last check Wednesday.